| Literature DB >> 24294205 |
Shinsuke Koike1, Yukika Nishimura, Ryu Takizawa, Noriaki Yahata, Kiyoto Kasai.
Abstract
Functional near-infrared spectroscopy (fNIRS) is a relatively new technique that can measure hemoglobin changes in brain tissues, and its use in psychiatry has been progressing rapidly. Although it has several disadvantages (e.g., relatively low spatial resolution and the possibility of shallow coverage in the depth of brain regions) compared with other functional neuroimaging techniques (e.g., functional magnetic resonance imaging and positron emission tomography), fNIRS may be a candidate instrument for clinical use in psychiatry, as it can measure brain activity in naturalistic position easily and non-invasively. fNIRS instruments are also small and work silently, and can be moved almost everywhere including schools and care units. Previous fNIRS studies have shown that patients with schizophrenia have impaired activity and characteristic waveform patterns in the prefrontal cortex during the letter version of the verbal fluency task, and part of these results have been approved as one of the Advanced Medical Technologies as an aid for the differential diagnosis of depressive symptoms by the Ministry of Health, Labor and Welfare of Japan in 2009, which was the first such approval in the field of psychiatry. Moreover, previous studies suggest that the activity in the frontopolar prefrontal cortex is associated with their functions in chronic schizophrenia and is its next candidate biomarker. Future studies aimed at exploring fNIRS differences in various clinical stages, longitudinal changes, drug effects, and variations during different task paradigms will be needed to develop more accurate biomarkers that can be used to aid differential diagnosis, the comprehension of the present condition, the prediction of outcome, and the decision regarding treatment options in schizophrenia. Future fNIRS researches will require standardized measurement procedures, probe settings, analytical methods and tools, manuscript description, and database systems in an fNIRS community.Entities:
Keywords: biological markers; clinical outcome; early intervention; near-infrared spectroscopy; verbal fluency task
Year: 2013 PMID: 24294205 PMCID: PMC3827961 DOI: 10.3389/fpsyt.2013.00145
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Figure 1Theoretical background and measurement settings of fNIRS. (A) Illustration of a simple source and detector probe set. When near-infrared light is emitted from a source probe onto the human scalp, it passes and scatters through brain tissues with relatively low absorption. Subsequently, part of this light is absorbed by blood hemoglobin in small vessels. A detector probe, normally placed 3 cm away from the source probe in adults, can detect scattered near-infrared light reflected by the surface of the cortex. (B) fNIRS measurement setting (ETG-4000, Hitachi Medical Corporation). Commercial fNIRS machines are small, movable, and work silently, so that they are easy to use in clinical settings. (C,D) 3 × 11 Probe attachment and fitting condition. Multi-channel fNIRS machines use multiple sources and detector probes and are able to measure brain activity between the probes. (A–C) Was approved by Hitachi Medical Corporation.
Comparison of CW-type fNIRS machines with other neuroimaging tools.
| fNIRS | fMRI | PET | EEG | MEG | ||
|---|---|---|---|---|---|---|
| Theoretical background | Signal property | Scattered near-infrared light | Magnetic property | Uptake of ligand marked positron | Collection of neural activity | Magnetic fields produced by brain’s electrical activity |
| Measurement area | Surface of the cortex | Surface of the cortex unless using depth EEG | Surface of the cortex | |||
| Time resolution (s) | 1 | 2–3 | ≥10 | |||
| Spatial resolution (mm) | 20 | 10 | 20 | 10 | ||
| Effect of extra-cortical tissue | Some | Some | None | |||
| Measurement setting | Invasiveness | Intravenous injection of radioactive ligand | ||||
| Body movement | No | No | No | No | ||
| Head restraint | Yes | Yes | Yes | |||
| Instrument | Size | Large, fix | Large, fix | Large in research use | Large, fix | |
| Transportability | No | No | Limited | No | ||
| Initial cost | Several million USD | Several million USD | Several million USD | |||
| Measurement and maintenance cost | Moderate | Very expensive (positron ligand) | Moderate | |||
Bold shows advantages compared to other neuroimaging tools.
.
Previous fNIRS studies in schizophrenia using verbal fluency tasks.
| Reference | Place | fNIRS instrument | Case demographics | ||||
|---|---|---|---|---|---|---|---|
| Model | Number of analyzed channels | Number of cases (M/F) | Mean age in cases (SD) | Medication | Recruitment places | ||
| Shimodera et al. ( | Kochi | OMM-3000/16 | 42 | 32 (12/19) | 42.4 (15.7) | All | University hospital |
| Koike et al. ( | Tokyo | ETG-4000 | 52 | 38 (22/16) | 31.3 (6.1) | All | University hospital, psychiatric hospital, health service center, and clinics |
| Takeshi et al. ( | Tokyo (Toho University) | OMM-3000/16 | 24 | 18 (7/11) | 25.4 (5.8) | All | NA |
| Azechi et al. ( | Osaka | OMM-3000/16 | 2 | 30 (16/14) | 39.6 (13.1) | All | University hospital |
| Quaresima et al. ( | L’Aquila | NIRO-300 | 2 | 9 (5/4) | 32.1 (8.3) | All | NA |
| Ikezawa et al. ( | Osaka | NIRO-200 | 2 | 30 (12/18) | 38.7 (11.7) | Two patients drug naïve | University hospital |
| Takizawa et al. ( | Tokyo | ETG-4000 | 52 | 55 (26/29) | 40.1 (11.1) | All | University hospital |
| Ehlis et al. ( | Wuerzburg | ETG-100 | 22 | 12 (9/3) | 34.2 (10.4) | One patient drug naïve | NA |
| Kubota et al. ( | Cleveland | NIRO-300 | 2 | 16 (8/8) | 37.5 (13.0) | All | NA |
| Suto et al. ( | Gunma | ETG-100 | 48 | 13 (9/4) | 37.9 (12.0) | All | University hospital |
| Watanabe and Kato ( | Ehime | HEO-200 | 1 | 62 (30/32) | 40.1 (12.3) | All | Psychiatric hospital |
| Shimodera et al. ( | 30-s Rest | 30-s × 2 Letter sets | 70-s Rest | ↓ | Bilateral FPC, DLPFC, and VLPFC regions | Bonferroni | |
| Koike et al. ( | 60-s Vowel repeats | 20-s × 3 Letter sets | 70-s Vowel repeats | ↓ | Bilateral FPC, DLPFC, and VLPFC regions | FDR | |
| Takeshi et al. ( | 60-s Vowel repeats | 20-s × 3 Letter sets | 70-s Vowel repeats | ↓ | Bilateral dorsal FPC and DLPFC | No | |
| Azechi et al. ( | 30-s Vowel repeats | 20-s × 3 Letter/category sets | 60-s Vowel repeats | ↓ | Bilateral FPC | No | |
| Quaresima et al. ( | 120-s Rest | 30-s × 4 Letter sets | No setting | ↓ | Bilateral FPC | No | |
| Ikezawa et al. ( | 30-s Vowel repeats | 20-s × 3 Letter/category sets | 60-s Vowel repeats | ↓ | Bilateral FPC | ANCOVA | |
| Takizawa et al. ( | 60-s Vowel repeats | 20-s × 3 Letter sets | 70-s Vowel repeats | ↓ | Bilateral FPC, DLPFC, and VLPFC regions | FDR | |
| Ehlis et al. ( | 10-s Rest | 30-s Letter/category and 30-s rest × 2 sets | 30-s Control task (repeatedly say weekdays) and 30-s rest between the sets of task conditions | ↓ | Left DLPFC and VLPFC | ANOVA | |
| Kubota et al. ( | 20-s A vowel repeats | 15-s × 6 Letter/category sets | No setting | ↓ | Bilateral FPC | ANOVA | |
| Suto et al. ( | 30-s Vowel repeats | 20-s × 3 Letter sets | 60-s Vowel repeats | – | – | ANOVA | |
| Watanabe and Kato ( | 15-s No detailed description | 60-s One letter set | 15-s No detailed description | ↓ | Left FPC | ANOVA | |
| Shimodera et al. ( | NA | n.s. | NA | ||||
| Koike et al. ( | Positive association in the FPC region in the chronic schizophrenia group | Positive association with PANSS positive or negative scores in the FEP group | n.s. (including no difference between UHR individuals with and without medication) | ||||
| Takeshi et al. ( | n.s., But positive association in the FPC during an idea fluency task | NA | NA | ||||
| Azechi et al. ( | NA | n.s. | n.s. | ||||
| Quaresima et al. ( | NA | NA | NA | ||||
| Ikezawa et al. ( | NA | n.s. | n.s. | ||||
| Takizawa et al. ( | Positive association in the FPC and right DLPFC regions | Negative correlation with age at measurement, positive correlation with PANSS positive score, and negative correlation with PANSS general psychopathology score in schizophrenia | n.s. | ||||
| Ehlis et al. ( | NA | NA | n.s. | ||||
| Kubota et al. ( | NA | NA | NA | ||||
| Suto et al. ( | NA | NA | NA | ||||
| Watanabe and Kato ( | NA | n.s. | n.s. | ||||
Excluded previous gene association studies.
NA, not applicable; n.s., no significant correlation; FPC, the frontopolar prefrontal cortex; DLPFC, dorsolateral prefrontal cortex; VLPFC, ventrolateral prefrontal cortex; FDR, false discovery rate; GAF, the global assessment of functioning; PANSS, the positive and negative symptom scale; FEP, first-episode psychosis, UHR, ultra-high risk.
.
.
.
.
.
.
.
Limitation of previous fNIRS studies and further implication.
| Limitation of previous studies | Further implications |
|---|---|
| Cross-sectional measurement for chronic and stable patients with medication | Measure in different clinical stages (e.g., UHR, FEP, recurrent phase) |
| Measure longitudinally to explore the relationship between clinical changes and fNIRS signals | |
| Measure in drug-naïve patients to explore drug effect | |
| Measure in a specific treatment response (e.g., medication, electroconvulsive therapy, neurofeedback) | |
| Measure in cohort setting (e.g., psychotic-like experiences) | |
| One-sided task procedure (block-designed VFTs) | Use of other cognitive tasks |
| Adopt event-related design | |
| Adopt more naturalistic task (e.g., driving, conversation) | |
| Small sample size in single institute | Make consortium with the same instrument and measurement procedure (e.g., task paradigm, probe setting) |
| Adopt more sophisticated analytical methods (e.g., measurement tools, bioinformatics, machine learning) | |
| Standardize manuscript description | |
| Construct fNIRS community |
UHR, ultra-high risk; FEP, first-episode psychosis.